A Prospective, Belgian Multi-center, Single-arm, Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04224922 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Stage Ii ◽

Weekly Paclitaxel ◽

Download Full-text

Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps110 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS110-TPS110 ◽

Author(s):

W. M. Sikov ◽

C. M. Perou ◽

M. Golshan ◽

D. Collyar ◽

D. A. Berry ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Trial ◽

Weekly Paclitaxel ◽

Randomized Phase Ii ◽

Download Full-text

Abstract PS13-51: A phase II study of neoadjuvant weekly carboplatin/paclitaxel followed by dose-dense doxorubicin/cyclophosphamide (DD AC)in patients with triple negative breast cancer (TNBC): Wisconsin oncology network (WON) study

10.1158/1538-7445.sabcs20-ps13-51 ◽

2021 ◽

Author(s):

Yee Chung Cheng ◽

Ruth O'Regan ◽

Lubna N Chaudhary ◽

Sailaja Kamaraju ◽

Harvey Einhorn ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Download Full-text

Abstract P5-16-06: Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology

10.1158/1538-7445.sabcs16-p5-16-06 ◽

2017 ◽

Author(s):

C Fontaine ◽

N Cappoen ◽

V Renard ◽

P Vuylsteke ◽

H Van Den Bulck ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Medical Oncology ◽

Phase Ii Study ◽

Breast Cancer Patients ◽

Belgian Society ◽

Download Full-text

Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2015.03.002 ◽

2015 ◽

Vol 15 (4) ◽

pp. 259-265 ◽

Author(s):

Giuseppe Cancello ◽

Vincenzo Bagnardi ◽

Claudia Sangalli ◽

Emilia Montagna ◽

Silvia Dellapasqua ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Preoperative Treatment ◽

Metronomic Cyclophosphamide

Download Full-text

179P Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A single-arm, open-label, phase II study

Annals of Oncology ◽

10.1016/j.annonc.2021.08.460 ◽

2021 ◽

Vol 32 ◽

pp. S436

Author(s):

C. Wang ◽

Z. Liu ◽

X. Chen ◽

J. Qiao ◽

L. Li ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Open Label Phase

Download Full-text

Abstract PS11-32: Mario-3 phase II study safety run-in evaluating a novel triplet combination of eganelisib (formerly IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs20-ps11-32 ◽

2021 ◽

Author(s):

Erika Hamilton ◽

Arielle Lee ◽

Rachel Swart ◽

Gina Newton ◽

Brenda O'Connell ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Locally Advanced ◽

Download Full-text

OT3-01-08: Phase II Study of S-1 Combined with Cisplatin in the First-Line Treatment of Triple Negative Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-08 ◽

2011 ◽

Author(s):

Y Fan ◽

BH Xu

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Abstract OT2-1-03: A pilot and phase II study of entinostat and anastrozole/tamoxifen in women with triple negative breast cancer (TNBC) to evaluate biomarkers and surrogates for response

10.1158/1538-7445.sabcs14-ot2-1-03 ◽

2015 ◽

Author(s):

Saranya Chumsri ◽

Gauri Sabnis ◽

Nancy Tait ◽

Jane Lewis ◽

Emily Bellavance ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Download Full-text

Abstract P5-15-15: Phase II study of navelbine plus carboplatin followed by oral navelbine in patients with metastatic/recurrent triple negative breast cancer previously treated with anthracycline and taxane

10.1158/1538-7445.sabcs16-p5-15-15 ◽

2017 ◽

Author(s):

W El-Sadda ◽

I Abdel Halim ◽

M El-Ibrashi

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Previously Treated

Download Full-text

Abstract P2-09-05: LCCC 1525: A phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer (mTNBC)

10.1158/1538-7445.sabcs18-p2-09-05 ◽

2019 ◽

Author(s):

CK Anders ◽

D Moore ◽

M Sambade ◽

L Cuaboy ◽

A Garrett ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Download Full-text